finance
FDA Approves Zoryve Cream 0.3% for Plaque Psoriasis in Children Age 2 and Older
The Food and Drug Administration approved Zoryve cream 0.3% for treating plaque psoriasis in children as young as age 2. The approval expands the prior indication that covered patients age 6 and older.
FI
fda.govAudio version
Tap play to generate a narrated version.
The approval expands an earlier indication that covered patients age 6 and older. The product is a topical treatment applied directly to affected skin.
Zoryve cream 0.3% was previously cleared for plaque psoriasis in patients age 6 and older. The new decision lowers the minimum age for use. The company that markets the product did not release additional details on timing or availability for the younger age group.
Health care providers can now consider the treatment for children meeting the updated age criteria. Further prescribing information will be updated to reflect the expanded indication.
Transparency
How sources framed this
FI
FI
These outlets didn't split into competing frames — coverage was uniform.
CorroborationModerate · 3 sources
